|
The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News: ---------- PHSC PLC - Aylesford, Kent-based provider of health, safety, hygiene and environmental consultancy and security solutions - Chair & Chief Executive Officer Stephen King resigns ‘to pursue other interests’, leaving on January 12. King was one of PHSC’s founders and has been involved in the business since its creation in 1990. Co-Founder Nicola Coote, who serves as deputy chair & deputy CEO, ‘remains fully involved in the business’, PHSC says. It is looking for a new CEO, while Non-Executive Chair Lorraine Young becomes non-executive chair immediately. Young has been on the board since 2016. ---------- Deltic Energy PLC - London-based investor with exploration and appraisal portfolio in southern and central North Sea - Graham Swindells resigns immediately as CEO, saying the company’s new focus on rebuilding a portfolio outside the UK means it is an appropriate time to go. Chief Operating Officer Andrew Nunn is promoted to CEO. Nunn has been with Deltic since 2014 and COO since 2015. He is geologist with 25 years experience and was involved in origination of the Pensacola discovery and of the Selene prospect, where the company currently is drilling. ‘Graham has led Deltic through some of the toughest and most volatile times I’ve ever experienced in this industry,’ Nunn says. ‘Our small team has delivered what would have been, at any other time in the industry’s history, a company-making success with the Pensacola discovery. Deltic has the potential for a second major discovery at Selene where drilling operations are ongoing.’ Late last month, Deltic said its pretax loss widened to £19.3 million in the six months that ended June 30 from £1.1 million a year before. It has no revenue. Cash stood at £3.7 million on June 30, down from £5.6 million on December 31. ---------- Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Hires Michelle Morrow as chief scientific officer, starting November 4. Says Morrow has 20 years experience in oncology therapeutics and antibody research at biotech and pharmaceutical companies. Most recently she was head of invoX Therapeutics Innovation at invoX Pharma Ltd. She has PhD in immunology from the University of Cambridge. ---------- Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
